Get the Stockscreener App
11.06
0.91%
0.10
89 Bio Inc stock is traded at $11.06, with a volume of 841.55K.
It is up +0.91% in the last 24 hours and up +68.09% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$10.96
Open:
$11.13
24h Volume:
841.55K
Relative Volume:
0.44
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-5.6142
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
+4.64%
1M Performance:
+68.09%
6M Performance:
+24.27%
1Y Performance:
+5.74%
1-Day Range:
$10.88
$11.23
1-Week Range:
$10.50
$11.31
52-Week Range:
$5.9857
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
11.06 | 1.59B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
89bio Inc (NASDAQ: ETNB) Is A Buzzing Hot Stock - Stocks Register
89bio, Inc. (NASDAQ:ETNB) Shares Sold by abrdn plc - MarketBeat
89bio (NASDAQ:ETNB) Shares Up 7.1%Time to Buy? - MarketBeat
FY2024 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
Recent uptick might appease Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners after losing 89% over the past year - Simply Wall St
Ra Capital Management, L.P. Buys 5,714,285 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock - MarketBeat
89bio Inc [ETNB] stock for 49,999,994 USD was acquired by RA CAPITAL MANAGEMENT, L.P. - Knox Daily
89bio (NASDAQ:ETNB) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside 89bio's Latest Executive Compensation Move: 163K Share Options Granted - StockTitan
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Yahoo Finance
SG Americas Securities LLC Has $284,000 Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Wolfe Research Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
What is Leerink Partnrs’ Forecast for 89bio FY2024 Earnings? - Defense World
89bio Inc [ETNB] gain 37.47% so far this year. What now? - The DBT News
89bio Inc (ETNB)’s Market Momentum: Closing Strong at 10.75, Up 15.72 - The Dwinnex
What is Leerink Partnrs’ Estimate for 89bio FY2029 Earnings? - Defense World
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation - MSN
89bio CEO awarded 200,000 restricted stock units By Investing.com - Investing.com Australia
89bio CEO awarded 200,000 restricted stock units - MSN
89bio Inc (NASDAQ: ETNB) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
ETNB’s Financial Health: Exploring 89bio Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Hedge Fund and Insider Trading News: Ken Griffin, Paul Singer, Greenlight Capital, Balyasny Asset Management, Ashland Inc (ASH), 89bio Inc (ETNB), and More - Insider Monkey
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet - MSN
FY2029 Earnings Forecast for 89bio Issued By Leerink Partnrs - MarketBeat
ETNB Insider Trade Alert! Majority Shareholder Sells $50M Worth of 89bio Stock - TipRanks
89bio, Inc. (NASDAQ:ETNB) Short Interest Up 12.2% in January - MarketBeat
89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss Ratings - Defense World
89bio Stock Upgraded to Buy: Positive SYMMETRY Study Data Reinforces FGF21 Analog Potential - TipRanks
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
Major Investment Alert: 89bio Stock Sees Multi-Million Dollar Boost! - TipRanks
Leerink raises 89bio stock target to $37 on NASH study optimism - Investing.com Canada
89bio Inc [ETNB] Insider Activity: An Update for Investors - Knox Daily
89bio Closes Public Offering, Raises $287.5 Mln - Nasdaq
89bio Closes $287.5 Million Public Offering -February 03, 2025 at 11:17 am EST - Marketscreener.com
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
89bio Secures Massive $287.5M Capital Injection: What This Means for NASH Treatment Future - StockTitan
Leerink raises 89bio stock target to $37 on NASH study optimism By Investing.com - Investing.com South Africa
89bio (NASDAQ:ETNB) Price Target Raised to $38.00 - Defense World
89bio (NASDAQ:ETNB) Shares Gap UpHere's Why - MarketBeat
UBS Group Issues Positive Forecast for 89bio (NASDAQ:ETNB) Stock Price - MarketBeat
89bio (NASDAQ:ETNB) Trading Up 8.3%Here's What Happened - MarketBeat
89bio (NASDAQ:ETNB) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets - Investing.com
89bio Inc (ETNB) Offers An Excellent Investment Opportunity At Current Levels - Stocks Register
89bio’s Pegozafermin Is Now Gaining Momentum (NASDAQ:ETNB) - Seeking Alpha
MASH momentum prompts $250 million raise for 89bio - The Pharma Letter
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
89 Bio Inc Stock (ETNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McWherter Charles | Director |
Jan 22 '25 |
Buy |
6.71 |
10,000 |
67,100 |
25,000 |
| McWherter Charles | Director |
Jan 21 '25 |
Buy |
6.55 |
5,000 |
32,750 |
15,000 |
| Le-Nguyen Quoc | See Remarks |
Jan 15 '25 |
Sale |
6.49 |
10,963 |
71,150 |
271,833 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):